Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17613605 | 0.86 | TDP1 (0.43) | TDP1 | |
| SCHEMBL15833401 | 0.85 | KDM4E (0.35) | TDP1 | |
| SCHEMBL12198870 | 0.83 | SMN1; SMN2 (0.39) | TDP1 | |
| SCHEMBL16647560 | 0.80 | — | — | |
| SCHEMBL2514266 | 0.80 | TDP1 (0.35) | TDP1 | |
| SCHEMBL7940467 | 0.79 | — | — | |
| SCHEMBL3864690 | 0.79 | TDP1 (0.50) | TDP1 | |
| SCHEMBL12149865 | 0.78 | RIPK1 (0.31) | TDP1 | |
| SCHEMBL15468707 | 0.78 | TSHR (0.32) | — | |
| SCHEMBL2171182 | 0.78 | TSHR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046964-B1 | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS BY REVERSIBLE PHOSPHOTRIESTER CHARGE NEUTRALIZATION PROTECTING GROUPS | UNIV CALIFORNIA (US) | 2018-07-04 | — | — | EP | claimed |
| US-20170145042-A1 | CYSTEINE-MODIFYING SUBSTRATE ANALOGUE INHIBITORS OF RIBOSE 5-PHOSPHATE ISOMERASE FOR PARASITIC DISEASES, ALONG WITH METHODS OF THEIR FORMATION AND USE | UNIVERSITY OF SOUTH CAROLINA | 2017-05-25 | — | — | US | claimed |
| US-12485135-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4617278-A1 | NUCLEOTIDE ANALOG, AND COMPOSITION AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-20250236623-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2025103477-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2025-05-22 | — | — | WO | disclosed |
| EP-4516798-A1 | NUCLEOSIDE DRUG FOR TREATING OR PREVENTING CORONAVIRUS INFECTION, AND USE THEREOF | Miracure Biotechnology Limited (CN) | 2025-03-05 | — | — | EP | disclosed |
| US-12202850-B2 | Cyclobutyl purine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2025-01-21 | — | — | US | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240350523-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2024-10-24 | — | — | US | disclosed |
| WO-2002008235-A1 | MEDICAMENT FOR ORAL APPLICATION, CONTAINING AMINOPROPYL PHOSPHONIC ACID ESTERS AS AN ACTIVE INGREDIENT | JOMAA PHARMAKA GMBH (DE) | 2002-01-31 | — | — | WO | disclosed |
| US-6274725-B1 | PROVIDING COMPOUND HAVING A HYDROXYL GROUP; REACTING WITH PHOSPHITYLATING REAGENT IN THE PRESENCE OF A PYRIDINUM SALT IN A SOLVENT UNDER CONDITIONS OF TIME, TEMPERATURE AND PRESSURE TO YIELD PHOSPHITYLATED COMPOUND | ISIS PHARMACEUTICALS, INC. | 2001-08-14 | — | — | US | disclosed |
| US-6124445-A | PRO DRUGS FOR OLIGONUCLEOTIDES HAVING BIOREVERSIBLE PHOSPHATE BLOCKING GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-26 | — | — | US | disclosed |
| WO-2000004032-A1 | UNSATURATED PHOSPONATES DERIVED FROM INDOLE | PIERRE FABRE MEDICAMENT (FR) | 2000-01-27 | — | — | WO | disclosed |
| US-5955591-A | OLIGONUCLEOTIDES HAVING BIOREVERSIBLE PHOSPHATE BLOCKING GROUPS; USED AS PRODRUGS; ANTISENSE AGENTS | CENTER NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1999-09-21 | — | — | US | disclosed |
| EP-0912592-A1 | PHOSPHOTRIESTER OLIGONUCLEOTIDES, AMIDITES AND METHOD OF PREPARATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997047637-A1 | PHOSPHOTRIESTER OLIGONUCLEOTIDES, AMIDITES AND METHOD OF PREPARATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (US) | 1997-12-18 | — | — | WO | disclosed |
| US-5627185-A | Acyclovir derivatives as antiviral agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1997-05-06 | — | — | US | disclosed |
| WO-1996033201-A1 | ACYCLOVIR DERIVATIVES AS ANTIVIRAL AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236623-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | TDP1 624/4885 |
| US-12202850-B2 | Cyclobutyl purine derivative or salt thereof | SLC28A1, SLC20A1, SLC29A1 | TDP1 404/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | TDP1 3760/4885 |
| US-12485135-B2 | Nicotinamide mononucleotide derivatives and their uses | NAMPT, NNT, NQO1 | TDP1 2917/4885 |
| US-20240350523-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | TDP1 2917/4885 |
| US-20170145042-A1 | CYSTEINE-MODIFYING SUBSTRATE ANALOGUE INHIBITORS OF RIBOSE 5-PHOSPHATE ISOMERASE FOR PARASITIC DISEASES, ALONG WITH METHODS OF THEIR FORMATION AND USE | RPIA, PRPS1, MPI | TDP1 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.